ArticleThe Korean journal of internal medicine2025
Live zoster vaccination and hepatobiliary risk reduction: a nationwide South Korean study.
Article in The Korean journal of internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hidden benefits beyond herpes zoster: a potential preventive strategy against hepatobiliary diseases.The Korean journal of internal medicine · 2025Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND/
aimsHerpes zoster (HZ) vaccination is primarily administered to prevent shingles, yet its systemic immunomodulatory effects may offer protection against other organ-related diseases, including hepatobiliary and pancreatic diseases. Therefore, this emulated target trial aimed to evaluate whether live HZ vaccination reduces the long-term risk of hepatobiliary diseases in older adults.
methodsWe conducted a nationwide, population-based cohort study in South Korea (n = 2,207,784 individuals aged ≥ 50 years) from January 1, 2012, to December 31, 2021, with follow-up until January 31, 2024. This cohort was built by merging health insurance (Korea Health Insurance Review and Assessment Service), national health screening (Korean National Health Insurance Service), and vaccination records (Korea Disease Control and Prevention Agency). To assess the risk of any hepatobiliary diseases and eight subcategories following HZ vaccination, we performed 1:1 exposure-driven propensity score matching and estimated adjusted hazard ratios (aHRs) using Cox proportional hazards models.
resultsAfter matching, 1,462,070 individuals were included (mean age, 61.57 years; 56.26% females). HZ vaccination was associated with a 14% lower risk of developing any hepatobiliary events (aHR 0.86, 95% CI 0.85-0.87). Risk reductions were consistent across all subcategories, notably for hepatic failure (aHR 0.71, 95% CI 0.63-0.78) and liver cirrhosis (aHR 0.74, 95% CI 0.70-0.77). Protective associations were more pronounced in males, younger individuals (< 60 years), and smokers. The benefit persisted for eight years, peaking within the first four years.
conclusionHZ vaccination was associated with significantly reducing hepatobiliary and pancreatic diseases, supporting potential broader health benefits beyond shingles prevention in older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.